Connor, Clark & Lunn Investment Management (CC&L)
CBPO

Connor, Clark & Lunn Investment Management (CC&L)’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,827
Closed -$493K – 1210
2020
Q2 		$493K Buy
+4,827
New +$517K ﹤0.01% 758

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CBPO Position: Q3 2020 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2020, closing a stake of 4,827 shares — an estimated $493K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CBPO in Q2 2020 and held it in 1 quarter. The position peaked at $493K in Q2 2020. 87 funds tracked by Wall St. Rank hold CBPO as of Q3 2020.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2020 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 4,827 China Biologic Products Holdings, Inc. shares in Q3 2020, an estimated $493K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in China Biologic Products Holdings, Inc. in Q2 2020 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s China Biologic Products Holdings, Inc. position peaked at $493K in Q2 2020.
  • 87 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2020.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2020, filed 12 Nov 2020.